HK1163689A1 - Methods and compositions for modulating ire1, src, and abl activity ire1src abl - Google Patents

Methods and compositions for modulating ire1, src, and abl activity ire1src abl

Info

Publication number
HK1163689A1
HK1163689A1 HK12104444.0A HK12104444A HK1163689A1 HK 1163689 A1 HK1163689 A1 HK 1163689A1 HK 12104444 A HK12104444 A HK 12104444A HK 1163689 A1 HK1163689 A1 HK 1163689A1
Authority
HK
Hong Kong
Prior art keywords
abl
ire1src
src
compositions
methods
Prior art date
Application number
HK12104444.0A
Other languages
English (en)
Chinese (zh)
Inventor
彼得．沃爾特
阿列克謝．科倫內赫
凱萬．
．肖卡特
張超
亞內特．芬納-莫爾
羅伯特．斯特勞德
帕斯卡爾．埃赫亞
安德烈．科羅斯捷列夫
阿爾文．達爾
塞巴斯蒂安．貝納萊斯
Original Assignee
加利福尼亞大學董事會
生命科學基金會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 加利福尼亞大學董事會, 生命科學基金會 filed Critical 加利福尼亞大學董事會
Publication of HK1163689A1 publication Critical patent/HK1163689A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK12104444.0A 2008-09-15 2012-05-08 Methods and compositions for modulating ire1, src, and abl activity ire1src abl HK1163689A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9717308P 2008-09-15 2008-09-15
PCT/US2009/056993 WO2010031056A2 (en) 2008-09-15 2009-09-15 Methods and compositions for modulating ire1, src, and abl activity

Publications (1)

Publication Number Publication Date
HK1163689A1 true HK1163689A1 (en) 2012-09-14

Family

ID=42005819

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12104444.0A HK1163689A1 (en) 2008-09-15 2012-05-08 Methods and compositions for modulating ire1, src, and abl activity ire1src abl

Country Status (8)

Country Link
US (2) US8815885B2 (xx)
EP (1) EP2340248B1 (xx)
JP (3) JP6144873B2 (xx)
CN (2) CN104230901A (xx)
AU (2) AU2009290617B2 (xx)
CA (1) CA2737388C (xx)
HK (1) HK1163689A1 (xx)
WO (1) WO2010031056A2 (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2737388C (en) * 2008-09-15 2017-07-11 Peter Walter Methods and compositions for modulating ire1, src, and abl activity
CA3042107C (en) 2009-11-03 2023-03-07 Fosun Orinove Pharmatech, Inc. Ire-1.alpha. inhibitors
US9956236B2 (en) 2011-02-07 2018-05-01 Cornell University Methods for increasing immune responses using agents that directly bind to and activate IRE-1
CA2846845C (en) 2011-09-02 2016-07-19 Children's Medical Center Corporation Methods and compositions for promoting glucose homeostasis
EP2754659A4 (en) * 2011-09-05 2015-08-26 Zhejiang Hisun Pharm Co Ltd 4-SUBSTITUTED- (3-SUBSTITUTED-1H-PYRAZOLE-5-AMINO) -PYRIMIDINES DERIVATIVES HAVING PROTEIN KINASE INHIBITION ACTIVITY AND USE THEREOF
US20150018406A1 (en) 2012-03-09 2015-01-15 Cornell University Modulation of breast cancer growth by modulation of xbp1 activity
EP2999472B1 (en) 2013-05-22 2020-07-22 The Regents of The University of California Aurora kinase inhibitors
DK3049521T3 (en) 2013-09-25 2019-04-23 Univ Cornell Compounds for inducing antitumor immunity and methods thereof
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
WO2016022839A1 (en) * 2014-08-06 2016-02-11 The Regents Of The University Of California Modulators of ire1
CN106162913B (zh) * 2015-04-21 2020-09-22 索尼公司 频谱协调装置和方法、无线通信系统中的装置和方法
WO2018138358A1 (en) * 2017-01-30 2018-08-02 Université de Liège Perk and ire-1a inhibitors against neurodevelopmental disorders
AR111281A1 (es) 2017-03-17 2019-06-26 Genentech Inc Compuestos de pirimidinil-piridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
TWI831829B (zh) * 2018-09-12 2024-02-11 美商建南德克公司 苯氧基-吡啶基-嘧啶化合物及使用方法
JP7098826B2 (ja) 2018-09-12 2022-07-11 ジェネンテック， インコーポレイテッド ピリミジニル－ヘテロアリールオキシ－ナフチル化合物および使用方法
TWI748317B (zh) 2019-01-03 2021-12-01 美商建南德克公司 吡啶并－嘧啶酮與喋啶酮化合物及使用方法
EP3927433A1 (en) 2019-02-18 2021-12-29 Genentech, Inc. Pyrido-pyrimidinyl compounds and methods of use
WO2020232403A1 (en) * 2019-05-15 2020-11-19 Cornell University Treatment of fibrosis with ire1 small molecule inhibitors
KR102215967B1 (ko) * 2019-05-28 2021-02-16 연세대학교 산학협력단 IRE1α 키나아제 활성화제를 유효성분으로 포함하는 단백질 형태 이상 질환의 예방 또는 치료용 조성물
WO2020252165A1 (en) 2019-06-11 2020-12-17 Genentech, Inc. Quinazolinyl compounds and methods of use
CN113966217A (zh) * 2019-06-14 2022-01-21 达萨玛治疗公司 Sarm1抑制剂
WO2022104151A1 (en) * 2020-11-13 2022-05-19 The Regents Of The University Of California Ire1alpha inhibitors and uses thereof
CN116710429A (zh) * 2020-11-13 2023-09-05 加利福尼亚大学董事会 IRE1α抑制剂及其用途
CN112616776B (zh) * 2021-01-04 2022-04-29 王涛 脊髓亚急性联合变性病模型的制备方法
CN114907350B (zh) * 2021-02-10 2023-12-29 上海凌达生物医药有限公司 一类含氮稠环类化合物、制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
CN1429222A (zh) 2000-02-17 2003-07-09 安姆根有限公司 激酶抑制剂
CA2422371C (en) 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20030105090A1 (en) * 2000-12-21 2003-06-05 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
WO2003026665A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
JP5208516B2 (ja) * 2004-12-30 2013-06-12 エグゼリクシス， インコーポレイテッド キナーゼモジュレーターとしてのピリミジン誘導体および使用方法
EP1746096A1 (en) * 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
US8222256B2 (en) 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
CA2737388C (en) 2008-09-15 2017-07-11 Peter Walter Methods and compositions for modulating ire1, src, and abl activity
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
JP5956597B2 (ja) 2011-11-10 2016-07-27 アプリックスＡｐｌｉｘ フックファスナー

Also Published As

Publication number Publication date
JP2012502916A (ja) 2012-02-02
US9382230B2 (en) 2016-07-05
US20110319436A1 (en) 2011-12-29
CN104230901A (zh) 2014-12-24
AU2015210470A1 (en) 2015-09-03
EP2340248A4 (en) 2012-06-20
AU2009290617A1 (en) 2010-03-18
CA2737388C (en) 2017-07-11
JP2017160197A (ja) 2017-09-14
JP6412968B2 (ja) 2018-10-24
CA2737388A1 (en) 2010-03-18
CN102264728A (zh) 2011-11-30
EP2340248B1 (en) 2017-05-31
CN102264728B (zh) 2015-02-04
AU2009290617B2 (en) 2015-05-14
WO2010031056A3 (en) 2010-08-05
US20150011575A1 (en) 2015-01-08
US8815885B2 (en) 2014-08-26
EP2340248A2 (en) 2011-07-06
JP2015017099A (ja) 2015-01-29
WO2010031056A2 (en) 2010-03-18
JP6144873B2 (ja) 2017-06-07

Similar Documents

Publication Publication Date Title
HK1163689A1 (en) Methods and compositions for modulating ire1, src, and abl activity ire1src abl
IL248652A0 (en) Methods, compositions and devices for facilitating re-creation
IL239959A0 (en) Compounds and methods for modulating kinases and their use
EP2068875A4 (en) COMPOSITIONS AND METHODS FOR MODULATING SIRTUIN ACTIVITY
EP2203058A4 (en) METHODS AND COMPOUNDS FOR MODULATING CANNABINOID ACTIVITY
EP2203067A4 (en) COMPOSITIONS AND METHODS USING CARBON MATERIALS
IL219567A0 (en) Compounds and methods for kinase modulation, and indications therefor
IL219418A0 (en) Compounds and methods for kinase modulation, and indications therefor
EP2516438A4 (en) COMPOUNDS AND METHODS FOR KINASE MODULATION AND DISPLAYS THEREFOR
EP2304520A4 (en) SYSTEMS AND METHODS OF COLLABORATING INTERACTIONS
EP2432774A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID RATES
EP2299828A4 (en) COMPOSITIONS FOR LOW USE AGRICULTURE AND METHODS OF USE
EP2197434A4 (en) COMPOSITIONS CONTAINING RESVERATROL FOR MODULATING THE CONCENTRATION OR ACTIVITY OF A GENE PRODUCT
PL2129680T3 (pl) Łączone kompozycje cząsteczek antysensownych o strukturze spinki do włosów oraz sposoby modulacji ekspresji
EP2235201A4 (en) METHODS AND COMPOSITIONS FOR THE ASSAY OF HOMOCYSTEINE
IL216388A0 (en) New compounds, pharmaceutical composition and methods relating thereto
HK1161543A1 (zh) 促進紅細胞生成的化合物和方法
EP2164978A4 (en) COMPOSITIONS AND METHODS FOR MODULATING ADAMTS13 ACTIVITY
EP2114981A4 (en) COMPOUNDS AND METHODS FOR MODULATING PROTEIN EXPRESSION
HUE047692T2 (hu) Gyógyászati készítmények és eljárások stabilizálásukra
EP2313516A4 (en) COMPOSITIONS AND METHODS FOR MODULATING THE NOD LIKE RECEPTOR ACTIVITY AND THEIR USE
EP2015782A4 (en) COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION
EP2205271A4 (en) COMPOSITIONS AND METHODS OF THERAPIES BASED ON RIBONUCLEASE BASE
HK1141682A1 (en) New compositions and methods for cell killing
HRP20150021T1 (xx) Spojevi fenantrenona, pripravci i postupci

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230915